Phaseline

Companies › Intra-IMMUSG Pte

Intra-IMMUSG Pte: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 3 Phase 2, 2 Phase 1; Oncology, Ophthalmology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PRL3-zumab
Humanized monoclonal antibody targeting phosphatase of regenerating liver-3 (PRL3)
PRL3Phase 2Advanced Malignant Solid Tumor; Solid Tumor; Advanced Solid Cancers; Neovascular Age Related Macular Degeneration …Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07541001PRL3-zumabPhase 2Advanced Malignant Solid TumorOncologyDec 2026
NCT04452955PRL3-zumabPhase 2Solid TumorOncologyDec 2026
NCT07290088PRL3-zumabPhase 2Advanced Solid CancersOncologyDec 2026
NCT07547228PRL3-zumabPhase 1Neovascular Age Related Macular DegenerationOphthalmologyFeb 2027
NCT03191682PRL3-zumabPhase 1Advanced Solid TumorsOncologyFeb 2027

Targets

PRL3 (1)

Companies with the same targets

–

Companies built like this

CrystalGenomics Partner Therapeutics STCube Ambrx Convergent Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.